The Short Answer
ARA-290, also called cibinetide, is an investigational peptide designed from the structure of erythropoietin (EPO), the hormone that drives red blood cell production. Researchers describe it as a nonhematopoietic helix-B peptide of EPO: it was built to keep EPO's tissue-protective, anti-inflammatory signaling without stimulating red blood cell production.
It has been tested in small Phase 2 trials, mainly for small fiber neuropathy (nerve pain and nerve-fiber loss) in people with sarcoidosis and in people with type 2 diabetes. Results were encouraging but early.
ARA-290 is not FDA-approved for any use. This guide is educational. It doesn't give dosing advice. Talk with a licensed clinician about any treatment.
How It's Supposed to Work
EPO acts through two different receptor setups. The classic EPO receptor pair drives red blood cell production. Tissue protection is linked to a different complex: the EPO receptor paired with the β-common receptor (CD131) (Collino 2014; Joshi 2014). ARA-290's trial investigators describe it as acting selectively on the innate repair receptor, which mediates tissue protection (Brines 2015). That selectivity is why it isn't expected to behave like EPO on blood counts.
What the Human Trials Found
| Study | Who | What was studied | Main findings |
|---|---|---|---|
| Heij 2012, Mol Med | 22 people with sarcoidosis and small fiber neuropathy symptoms | 2 mg IV three times weekly vs placebo for 4 weeks | Neuropathy symptom score (SFNSL) improved more than placebo. General pain (BPI) and fatigue improved in both groups equally. No safety concerns reported |
| Dahan 2013, Mol Med | People with sarcoidosis-associated small nerve fiber loss | Daily subcutaneous ARA-290 vs placebo for 28 days | Better neuropathic symptoms, higher corneal nerve fiber density, longer 6-minute walk |
| Brines 2015, Mol Med (Phase 2) | People with type 2 diabetes and painful neuropathy | 4 mg subcutaneous daily vs placebo for 28 days, then 1 month off | Improved HbA1c and lipids over 56 days, better PainDetect scores. No safety issues identified |
| Culver 2017, IOVS (Phase 2b) | 64 people with sarcoidosis-associated nerve fiber loss and pain | 1, 4 or 8 mg/day vs placebo for 28 days | Corneal nerve fiber area rose significantly only in the 4 mg group. Pain improved in all study groups, and the placebo-corrected pain drop at 4 mg (moderate-to-severe pain) wasn't statistically significant (P = 0.157) |
Doses above are the amounts used in those research protocols, reported for context. They aren't recommendations.
How to Read These Results
- Small and short. The trials ran about four weeks and enrolled dozens of people, not thousands.
- Mixed on pain. Nerve-fiber measures moved in the right direction, but in the largest trial (Culver 2017) pain improved across all study groups and the placebo-corrected pain benefit wasn't statistically significant.
- One research group. The trials share authors affiliated with Araim Pharmaceuticals (the sponsor of the Phase 2b study) and Leiden University Medical Center. Independent replication is limited.
- No approval path yet. The Phase 2b sarcoidosis study (NCT02039687) is listed as completed on ClinicalTrials.gov, and a later diabetic macular edema study (NCT06626971) is listed as terminated after enrolling 9 people, with the reason given as expiry of the study drug and no replacement available.
ARA-290 Side Effects
In the published trials, investigators reported no safety concerns over roughly four weeks of treatment (Heij 2012; Brines 2015). That's reassuring for a short study, but it isn't the same as long-term safety data, and these were small groups. Products sold online outside of trials aren't checked by FDA for identity, purity or sterility. Our peptide certificate of analysis guide covers what a real test report should show.
If you have neuropathy symptoms, a licensed clinician can look for the cause (diabetes, B12 levels, thyroid, sarcoidosis and others) and discuss treatments with stronger evidence.
Tracking With Your Clinician
Neuropathy changes slowly, so consistent notes matter: pain scores, numbness, sleep, walking distance and anything you're taking. Save this in the PeptIQ app: PeptIQ keeps those notes on one timeline you can share with your care team.
Related reading: the ARA-290 research profile, KPV peptide benefits and the wellness peptide evidence gap.
